Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

1.7K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.7K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.7K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.7K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

2.7K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.7K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MFN2-Mediated MERCs Promote Odontoblast Differentiation and Dentinogenesis.

Journal of dental research·2026
Same author

Multiple acyl-coenzyme A dehydrogenase deficiency presenting with myopathy and hypoglycaemia: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi·2026
Same author

A rare mutation in THRB gene of resistance to thyroid hormone: a case report of a Chinese pedigree.

QJM : monthly journal of the Association of Physicians·2024
Same author

Associations between abdominal obesity indices with hypertension in type 2 diabetes mellitus: Chinese visceral adiposity index.

Journal of endocrinological investigation·2023
Same author

Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS.

Journal of endocrinological investigation·2022
Same author

Dlx3 Ubiquitination by Nuclear Mdm2 Is Essential for Dentinogenesis in Mice.

Journal of dental research·2022

Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.7K

Towards next generation adenosine A(2A) receptor antagonists.

G Yuan, G B Jones1

  • 1Department of Chemistry and Chemical Biology, Northeastern University, USA. gr.jones@neu.edu.

Current Medicinal Chemistry
|September 2, 2014
PubMed
Summary

Adenosine A2A receptor antagonists show promise as anti-Parkinson and cancer immunotherapies. This review covers their discovery, development, and medicinal evaluation.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

Related Experiment Videos

Last Updated: Apr 25, 2026

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research
04:43

Author Spotlight: Insights and Innovations in Gene Expression Manipulation Techniques for Choroid Plexus Research

Published on: June 16, 2023

1.7K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

10.3K
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.1K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Medicinal Chemistry

Background:

  • The Adenosine A2A receptor, a G-protein coupled receptor, is crucial in central nervous system and peripheral tissue functions.
  • Interactions between Adenosine A2A and dopamine D2 receptors highlight potential therapeutic applications.
  • Adenosine A2A antagonists are being explored for treating Parkinson's disease and as cancer immunotherapeutics.

Purpose of the Study:

  • To review the discovery, development, chemical synthesis, and medicinal evaluation of Adenosine A2A receptor antagonists.
  • To provide an overview of classical xanthine-type antagonists and second-generation agents.

Main Methods:

  • Literature review of studies on Adenosine A2A receptor antagonists.
  • Analysis of chemical synthesis and medicinal evaluation data.
  • Exploration of drug discovery and development pathways.

Main Results:

  • Adenosine A2A antagonists have demonstrated potential in preclinical and clinical studies.
  • The development has progressed from early xanthine derivatives to more advanced compounds.
  • These antagonists are recognized for their dual role in neuroprotection and immunomodulation.

Conclusions:

  • Adenosine A2A receptor antagonists represent a significant class of drugs with diverse therapeutic potential.
  • Further research and development are warranted to optimize their efficacy and safety for clinical use.
  • The review underscores the importance of Adenosine A2A receptor antagonists in modern drug discovery for neurological disorders and oncology.